Calcium D-Glucarate for Cancer Prevention
Calcium D-glucarate has not been shown to prevent cancer in people. The case for it rests entirely on laboratory and animal work plus a plausible mechanism, with no completed human trials to back it up.
Why this grade7-layer evidence engine
The evidence here is graded Unverified because it never reaches the human-outcome level. Every primary source in the PubMed record is a review, mechanism paper, or animal study: rat pharmacokinetics showing the active beta-glucuronidase inhibitor 1,4-glucarolactone is absorbed and excreted (PMID 9101079), a mouse lung-tumor mechanism report (PMID 15136472), and narrative monographs and commentaries calling for trials that were never run (PMID 7744577, PMID 12197785, PMID 15035900). None reports efficacy in people.
Major institutions are explicit. Memorial Sloan Kettering states that although lab studies suggest anticancer effects, calcium glucarate has not been shown to treat or prevent cancer in humans. The American Cancer Society does not recommend any dietary supplement for cancer prevention. US and EU regulators have issued no review or approval for this use.
Two caveats sharpen the verdict. The 1995 Heerdt paper (PMID 7744577) is widely miscited in supplement marketing as a breast-cancer Phase 1 trial, but it is indexed as a review and reports no trial data. And Health Canada's product licence covers only support of liver glucuronidation, not cancer prevention, so it should not be read as an anticancer endorsement.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.396
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism)，不足以下結論
- tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative；實際 E10)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status